ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

enekinragene inzadenovec

Also written as “FX201” and “Enekinragene Inzadenovec (PCRX-201)”.

Its studies are mostly in Osteoarthritis, Knee, led by Pacira BioSciences.

Furthest: phase 2, since Mar 13, 20252 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pacira BioSciences22 open or runningphase 2since Mar 13, 2025Oct 3, 2019Nov 2026phase 2 · NCT06884865

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 3, 2019First study: phase 1 study in Osteoarthritis, KneeFirst studyNCT04119687 · 72 enrolled · United States
  2. Jul 21, 2022Named enekinragene inzadenovecINNProposed as its International Nonproprietary Name in WHO's List 127 · before, FX201
  3. Mar 13, 2025Phase 2 study in OsteoarthritisNCT06884865 · 135 planned · United States

Ahead

  1. Nov 2026Primary completion: phase 2 study in OsteoarthritisNCT06884865

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06884865Osteoarthritis · United States2RecruitingNov 2026135
NCT04119687Osteoarthritis, Knee · United States1Active, not recruitingNov 28, 202372

How it is read

Names in the registry

  • “FX201”, 1 entry
  • “Enekinragene Inzadenovec (PCRX-201)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.